LTC1781789I2 - Timidinkinazė - Google Patents

Timidinkinazė

Info

Publication number
LTC1781789I2
LTC1781789I2 LTPA2016047C LTPA2016047C LTC1781789I2 LT C1781789 I2 LTC1781789 I2 LT C1781789I2 LT PA2016047 C LTPA2016047 C LT PA2016047C LT PA2016047 C LTPA2016047 C LT PA2016047C LT C1781789 I2 LTC1781789 I2 LT C1781789I2
Authority
LT
Lithuania
Prior art keywords
kinase
timidin
nucleotides
splice
polynucleotide
Prior art date
Application number
LTPA2016047C
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of LTPA2016047I1 publication Critical patent/LTPA2016047I1/lt
Publication of LTC1781789I2 publication Critical patent/LTC1781789I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
LTPA2016047C 2004-06-18 2016-12-28 Timidinkinazė LTC1781789I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413702.2A GB0413702D0 (en) 2004-06-18 2004-06-18 Thymidine kinase
PCT/IB2005/002358 WO2005123912A2 (en) 2004-06-18 2005-06-17 Thymidine kinase

Publications (2)

Publication Number Publication Date
LTPA2016047I1 LTPA2016047I1 (lt) 2017-01-25
LTC1781789I2 true LTC1781789I2 (lt) 2018-10-10

Family

ID=32750189

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2016047C LTC1781789I2 (lt) 2004-06-18 2016-12-28 Timidinkinazė

Country Status (21)

Country Link
US (5) US8357788B2 (lt)
EP (1) EP1781789B1 (lt)
JP (1) JP5091669B2 (lt)
KR (1) KR101337210B1 (lt)
CN (1) CN101010428B (lt)
AT (1) ATE520779T1 (lt)
AU (1) AU2005254807B2 (lt)
CA (1) CA2569304C (lt)
CY (2) CY1111925T1 (lt)
DK (1) DK1781789T3 (lt)
ES (1) ES2372022T3 (lt)
GB (1) GB0413702D0 (lt)
HK (1) HK1097881A1 (lt)
HU (1) HUS1600064I1 (lt)
IL (2) IL179660A (lt)
LT (1) LTC1781789I2 (lt)
NL (1) NL300856I2 (lt)
PL (1) PL1781789T3 (lt)
PT (1) PT1781789E (lt)
SI (1) SI1781789T1 (lt)
WO (1) WO2005123912A2 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
KR20140068259A (ko) 2011-10-05 2014-06-05 몰메드 에스피에이 바이러스 벡터 정제 시스템
KR102077648B1 (ko) * 2017-12-28 2020-02-14 주식회사 바이오녹스 안전성 및 항암효과가 개선된 종양 용해 바이러스
US11157042B1 (en) 2018-03-28 2021-10-26 Douglas Patton Systems and methods for interaction of wearable communication devices
CA3102055A1 (en) 2018-05-30 2019-12-05 Glycostem Therapeutics B.V. Car nk cells
EP3992281A4 (en) * 2019-06-27 2023-07-26 Bionoxx Inc. ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECT

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0758387B1 (en) * 1994-05-02 2001-12-19 University of Washington Thymidine kinase mutants
FR2751988B1 (fr) 1996-08-01 1998-09-11 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2744731B1 (fr) 1996-02-09 1998-05-22 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
BR9707483A (pt) * 1996-02-09 1999-04-06 Rhone Poulenc Rorer Sa Sequência de ácidos nucléicos que codificam para uma timidina quinase variante de uma timidina quinase selvagem variante de uma timidina quinase do vírus do herpes simplex de tipo 1 veículo de expressão vetor e composição farmacêutica
WO1997037542A1 (en) 1996-04-10 1997-10-16 University Of Southern California Gene therapy for proliferative vitreoretinopathy
EP2298350A3 (en) 1996-07-26 2011-06-08 Susan P. Perrine Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
EP1025212B1 (en) 1997-10-14 2007-09-26 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
EP1428886B1 (de) * 2002-12-09 2009-08-05 Celltech GmbH Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase

Also Published As

Publication number Publication date
KR101337210B1 (ko) 2013-12-06
CY1111925T1 (el) 2015-11-04
IL213084A0 (en) 2011-07-31
US20140178345A1 (en) 2014-06-26
EP1781789A2 (en) 2007-05-09
US10314925B2 (en) 2019-06-11
ES2372022T3 (es) 2012-01-13
EP1781789B1 (en) 2011-08-17
IL179660A0 (en) 2007-05-15
NL300856I2 (lt) 2017-04-20
WO2005123912A3 (en) 2006-05-04
SI1781789T1 (sl) 2012-03-30
US8357788B2 (en) 2013-01-22
US9005945B2 (en) 2015-04-14
CY2016054I2 (el) 2017-07-12
KR20070032786A (ko) 2007-03-22
CN101010428B (zh) 2013-10-02
AU2005254807B2 (en) 2011-08-18
WO2005123912A2 (en) 2005-12-29
HK1097881A1 (en) 2007-07-06
JP2008502342A (ja) 2008-01-31
US20190070312A1 (en) 2019-03-07
US20150231275A1 (en) 2015-08-20
JP5091669B2 (ja) 2012-12-05
CN101010428A (zh) 2007-08-01
US10155052B2 (en) 2018-12-18
PT1781789E (pt) 2011-10-20
CY2016054I1 (el) 2017-07-12
PL1781789T3 (pl) 2011-12-30
CA2569304A1 (en) 2005-12-29
US8642311B2 (en) 2014-02-04
AU2005254807A1 (en) 2005-12-29
ATE520779T1 (de) 2011-09-15
IL179660A (en) 2012-12-31
GB0413702D0 (en) 2004-07-21
US20130028876A1 (en) 2013-01-31
CA2569304C (en) 2014-08-12
DK1781789T3 (da) 2011-11-28
HUS1600064I1 (hu) 2017-02-28
US20090130069A1 (en) 2009-05-21
LTPA2016047I1 (lt) 2017-01-25

Similar Documents

Publication Publication Date Title
LTC1781789I2 (lt) Timidinkinazė
DE602006015405D1 (de) Inkrementelle Assoziation von Metadaten zu Produktionsdaten
CY2018019I1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
DK1966195T3 (da) 5-arylisoxazoliner til bekæmpelse af hvirvelløse skadedyr
BRPI0819184A2 (pt) variantes de alfa-amilase com propriedades alteradas.
DE60232245D1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
ATE474614T1 (de) Verbesserter pen-injektor
CY1109892T1 (el) Φυτα ανθεκτικα στην πιεση
DK1749921T3 (da) Brandhæmmende, syntetisk læder
DE602007003410D1 (de) Datenschutzgerechte Verknüpfung von Zeichenfolgen
ATE315585T1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
CY1111486T1 (el) Μιμητικα αντισωματα (mimetibodies) δεσμευμενα με υποδοχεα μελανοκορτινης, συνθεσεις, μεθοδοι και χρησεις
DE502004009010D1 (de) Prozessor mit verschiedenartigen steuerwerken für gemeinsam genutzte ressourcen
DE602007010248D1 (de) Rehydrierung von brennstoffzellen
ATE438726T1 (de) Modulation der anzahl von pflanzenzellen
ATE497991T1 (de) Phosphitester enthaltende stabilisatorzusammensetzung
EA200801927A1 (ru) Усовершенствованный грохот
BRPI0716763A2 (pt) grande de chapa delgada énica com bulbo reforÇado
ITTO20050108A1 (it) Trasmissione idrostatica a variazione continua.
ATE543828T1 (de) Heteropolynukleotid-duplexe mit purin-purin- paarung
ATE501160T1 (de) Neues markiertes oligonukleotid
DE50307207D1 (de) Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika
TR200704119A2 (tr) Bir toprak işleme makinası
ATE443929T1 (de) Enzymatische brennstoffzelle
FR2853906B1 (fr) N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications